Muscular Dystrophies clinical trials at UCSD
3 in progress, 2 open to eligible people
CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
open to eligible males ages 10 years and up
HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during the first 12-months of the study. All participants will be eligible to receive 4 doses of CAP-1002 for an additional 12 months as part of an open-label extended assessment period.
La Jolla, California and other locations
AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
open to eligible people ages 16-70
A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
San Diego, California and other locations
AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD)
Sorry, accepting new patients by invitation only
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, Efficacy, and Pharmacokinetics of AOC 1020 Administered Intravenously to Adult Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
San Diego, California and other locations
Last updated: